Literature DB >> 17192389

K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.

Margaret E M Van Meter1, Ernesto Díaz-Flores, Joehleen A Archard, Emmanuelle Passegué, Jonathan M Irish, Nikesh Kotecha, Garry P Nolan, Kevin Shannon, Benjamin S Braun.   

Abstract

Defining how cancer-associated mutations perturb signaling networks in stem/progenitor populations that are integral to tumor formation and maintenance is a fundamental problem with biologic and clinical implications. Point mutations in RAS genes contribute to many cancers, including myeloid malignancies. We investigated the effects of an oncogenic Kras(G12D) allele on phosphorylated signaling molecules in primary c-kit(+) lin(-/low) hematopoietic stem/progenitor cells. Comparison of wild-type and Kras(G12D) c-kit(+) lin(-/low) cells shows that K-Ras(G12D) expression causes hyperproliferation in vivo and results in abnormal levels of phosphorylated STAT5, ERK, and S6 under basal and stimulated conditions. Whereas Kras(G12D) cells demonstrate hyperactive signaling after exposure to granulocyte-macrophage colony-stimulating factor, we unexpectedly observe a paradoxical attenuation of ERK and S6 phosphorylation in response to stem cell factor. These studies provide direct biochemical evidence that cancer stem/progenitor cells remodel signaling networks in response to oncogenic stress and demonstrate that multi-parameter flow cytometry can be used to monitor the effects of targeted therapeutics in vivo. This strategy has broad implications for defining the architecture of signaling networks in primary cancer cells and for implementing stem cell-targeted interventions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17192389      PMCID: PMC1874575          DOI: 10.1182/blood-2006-09-047530

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

Review 1.  Focus on myeloproliferative diseases and myelodysplastic syndromes.

Authors:  Richard A Van Etten; Kevin M Shannon
Journal:  Cancer Cell       Date:  2004-12       Impact factor: 31.743

Review 2.  Signal transduction via Ras.

Authors:  A Wittinghofer
Journal:  Biol Chem       Date:  1998 Aug-Sep       Impact factor: 3.915

Review 3.  Stem cell factor and hematopoiesis.

Authors:  V C Broudy
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

4.  Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo.

Authors:  J S Sebolt-Leopold; D T Dudley; R Herrera; K Van Becelaere; A Wiland; R C Gowan; H Tecle; S D Barrett; A Bridges; S Przybranowski; W R Leopold; A R Saltiel
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

5.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell.

Authors:  D Bonnet; J E Dick
Journal:  Nat Med       Date:  1997-07       Impact factor: 53.440

6.  An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis.

Authors:  Alejandro Sweet-Cordero; Sayan Mukherjee; Aravind Subramanian; Han You; Jeffrey J Roix; Christine Ladd-Acosta; Jill Mesirov; Todd R Golub; Tyler Jacks
Journal:  Nat Genet       Date:  2004-12-19       Impact factor: 38.330

7.  The long-term repopulating subset of hematopoietic stem cells is deterministic and isolatable by phenotype.

Authors:  S J Morrison; I L Weissman
Journal:  Immunity       Date:  1994-11       Impact factor: 31.745

8.  Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.

Authors:  Toshiyuki Araki; M Golam Mohi; Fraz A Ismat; Roderick T Bronson; Ifor R Williams; Jeffery L Kutok; Wentian Yang; Lily I Pao; D Gary Gilliland; Jonathan A Epstein; Benjamin G Neel
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

9.  Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia.

Authors:  D A Largaespada; C I Brannan; N A Jenkins; N G Copeland
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

10.  Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.

Authors:  Doan T Le; Namie Kong; Yuan Zhu; Jennifer O Lauchle; Abigail Aiyigari; Benjamin S Braun; Endi Wang; Scott C Kogan; Michelle M Le Beau; Luis Parada; Kevin M Shannon
Journal:  Blood       Date:  2004-02-24       Impact factor: 22.113

View more
  69 in total

Review 1.  Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.

Authors:  Anica Wandler; Kevin Shannon
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

2.  Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.

Authors:  Neha Parikh; Ryan L Shuck; Thuy-Ai Nguyen; Alan Herron; Lawrence A Donehower
Journal:  Mol Cancer Res       Date:  2012-04-24       Impact factor: 5.852

3.  Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

Authors:  Nitin Jain; Emily Curran; Neil M Iyengar; Ernesto Diaz-Flores; Rangesh Kunnavakkam; Leslie Popplewell; Mark H Kirschbaum; Theodore Karrison; Harry P Erba; Margaret Green; Xavier Poire; Greg Koval; Kevin Shannon; Poluru L Reddy; Loren Joseph; Ehab L Atallah; Philip Dy; Sachdev P Thomas; Scott E Smith; L Austin Doyle; Walter M Stadler; Richard A Larson; Wendy Stock; Olatoyosi Odenike
Journal:  Clin Cancer Res       Date:  2013-10-31       Impact factor: 12.531

4.  USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism.

Authors:  Johanna Melo-Cardenas; Yuanming Xu; Juncheng Wei; Can Tan; Sinyi Kong; Beixue Gao; Elena Montauti; Gina Kirsammer; Jonathan D Licht; Jindan Yu; Peng Ji; John D Crispino; Deyu Fang
Journal:  Blood       Date:  2018-05-29       Impact factor: 22.113

5.  Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.

Authors:  Gordon Chan; Demetrios Kalaitzidis; Tatiana Usenko; Jeffery L Kutok; Wentian Yang; M Golam Mohi; Benjamin G Neel
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

6.  Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm.

Authors:  Guangyao Kong; Mark Wunderlich; David Yang; Erik A Ranheim; Ken H Young; Jinyong Wang; Yuan-I Chang; Juan Du; Yangang Liu; Sin Ruow Tey; Xinmin Zhang; Mark Juckett; Ryan Mattison; Alisa Damnernsawad; Jingfang Zhang; James C Mulloy; Jing Zhang
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

7.  Biochemical and functional characterization of germ line KRAS mutations.

Authors:  Suzanne Schubbert; Gideon Bollag; Natalya Lyubynska; Hoa Nguyen; Christian P Kratz; Martin Zenker; Charlotte M Niemeyer; Anders Molven; Kevin Shannon
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

8.  K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.

Authors:  Thomas Kindler; Melanie G Cornejo; Claudia Scholl; Jianing Liu; Dena S Leeman; J Erika Haydu; Stefan Fröhling; Benjamin H Lee; D Gary Gilliland
Journal:  Blood       Date:  2008-07-28       Impact factor: 22.113

Review 9.  Engineering mouse models with myelodysplastic syndrome human candidate genes; how relevant are they?

Authors:  Stephanie Beurlet; Christine Chomienne; Rose Ann Padua
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

10.  Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer.

Authors:  Ines Macias-Perez; Corina Borza; Xiwu Chen; Xuexian Yan; Raquel Ibanez; Glenda Mernaugh; Lynn M Matrisian; Roy Zent; Ambra Pozzi
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.